Лерканидипин при артериальной гипертензии
Аннотация
Лерканидипин – липофильный дигидропиридиновый (ДГП) антагонист кальция (АК) с продолжительным рецепторным периодом полужизни. Замедленное начало действия позволяет предотвратить развитие рефлекторной тахикардии, характерной для других ДГП АК. Лерканидипин обеспечивает равномерный и продолжительный антигипертензивный эффект при приеме 1 раз в сутки. Он обладает эквивалентной антигипертензивной активностью по отношению ко многим другим препаратам, являясь эффективным при монотерапии, так и в комбинации с другими средствами. Эффективность лерканидипина была продемонстрирована у различных возрастных групп пациентов, имеющих дополнительные факторы риска. Лерканидипин хорошо переносится: побочные эффекты, типичные для ДГП АК, возникают в самом начале лечения. На фоне приема лерканидипина частота отеков голеней, приводящих к последующей отмене терапии, ниже, чем при лечении амлодипином и нифедипином-GITS. В доклинических и клинических исследованиях было показано, что лерканидипин обладает антиатеросклеротическим действием и уменьшает гипертрофию левого желудочка. Эффективность и хорошая переносимость лерканидипина делают его препаратом выбора для лечения артериальной гипертензии у различных клинических групп пациентов.
Об авторе
K. Борджи
Университет Болоньи
Италия
Италия
Отдел Клинической медицины и прикладной биотехнологии “Де Кампаначи”
Болонья
Список литературы
1. [ADA] American Diabetes Association; Arauz-Pacheco C, Parrott MA, et al. 2004. Hypertension management in adults with diabetes. Diabetes Care, 27(Suppl 1):S65–7.
2. ALLHAT Officers and Coordinators. 2002. Major outcomes in high-risk hypertensive patients randomized to angiotensinconverting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA, 288:2981–97.
3. Angelico P, Guarneri L, Leonardi A, et al. 1999. Vascularselective effect of lercanidipine and other 1,4-dihydropyridines in isolated rabbit tissues. J Pharm Pharmacol, 51:709–14.
4. Aranda P, Aranda FJ, Bianchi JL, et al. 2000. Therapeutic efficacy and tolerability of lercanidipine versus candesartan, alone or in combination, in mild-moderate essential hypertensives. J Hypertens, 18(Suppl 2):S152.
5. Bang LM, Chapman TM, Goa KL. 2003. Lercanidipine: a review of its efficacy in the management of hypertension. Drugs, 63:2449–72.
6. Barbagallo M, Barbagallo SG. 2000. Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension. Aging (Milano), 12:375–9.
7. Barrios V, Calderon A, Navarro A, et al. 2004a. Lercanidipine effectiveness and tolerability profile is not influenced by overweight or body fat increase. The LERZAMIG study. J Hypertens, 22(Suppl 2):S258–9.
8. Barrios V, Calderon A, Navarro A, et al. 2004b. Lercanidipine is an effective and well tolerated drug in essential hypertension, independently of the cardiovascular risk. The Laura study. J Hypertens, 22(Suppl 2):S235.
9. Barrios V, Navarro A, Esteras A, et al. 2002. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE Study. Eficacia de Lercanidipino y su Perfil de Seguridad. Blood Press, 11:95–100.
10. Bellosta S, Bernini F. 2000. Lipophilic calcium antagonists in antiatherosclerotic therapy. Curr Atheroscler Rep, 2:76–81.
11. Borghi C, Prandin MG, Dormi A, et al. 2003. Improved tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the lercanidipine challenge trial. Blood Press, Suppl 1:14–21.
12. Brown MJ, Palmer CR, Castaigne A, et al. 2000. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet, 356:366– 72.
13. Calvo C, Hermida RC, Navarro A. 2002. Treatment of elderly hypertensive patients. preliminary results from the zanycal study [abstract]. Am J Hypertens, 15:110A.
14. Cavallini A, Terzi G. 2000. Effects of antihypertensive therapy with lercanidipine and verapamil in cardiac electrical activity in patients with hypertension: a randomised, double-blind pilot study. Curr Ther Res, 61:477–87.
15. Cesarone MR, Incandela L, Ledda A, et al. 2000. Pressure and microcirculatory effects of treatment with lercanidipine in hypertensive patients and in vascular patients with hypertension. Angiology, 51: S53–63.
16. Cherubini A, Fabris F, Ferrari E, et al. 2003. Comparative effects of lercanidipine, lacidipine, and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LErcanidipine (ELLE) study. Arch Gerontol Geriatr, 37:203–12.
17. Chobanian AV, Bakris GL, Black HR, et al. 2003. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 42:1206–52.
18. Cifkova R, Erdine S, Fagard R, et al. 2003. Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens, 21:1779–86.
19. Cleophas TJ, van Ouwerkerk BM, van der MJ, et al. 2001. Diabetics with hypertension not controlled with ACE inhibitors: alternate therapies Angiology, 52:469–75.
20. Collins R, Peto R, MacMahon S, et al. 1990. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet, 335:827–38.
21. Dalla Vestra M, Pozza G, Mosca A, et al. 2004. Effect of lercanidpine compared with ramipril on albumin excretion rate in hypertensive type 2 diabetic patients with microalbuminuria: DIALstudy(Diabete,Ipertensione,Albuminuria,Lercanidipina). Diab Nutr Metab, 17: 259–66.
22. De Giorgio LA, Orlandini F, Malasoma P, et al. 1999. Doubleblind, crossover study of lercanidipine versus amlodipine in the treatment of mild-to-moderate essential hypertension. Curr Ther Res, 60: 511–20.
23. Digiesi V, Fiorillo C, Cosmi L, et al. 2000. Reactive oxygen species and antioxidant status in essential arterial hypertension during therapy with dihydropyridine calcium channel antagonists. Clin Ter, 151:15–8.
24. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003. 2003 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens, 21:1011– 53.
25. Fogari R, Malamani GD, Zoppi A, et al. 2000. Comparative effect of lercanidipine and nifedipine gastrointestinal therapeutic system on ankle volume and subcutanous interstitial pressure in hypertensive patients: a double-blind, randomised, parallelgroup study. Curr Ther Res Clin Exp, 61:850–62.
26. Fogari R, Mugellini A, Corradi L, et al. 2000. Efficacy of lercanidipine vs losartan on left ventricular hypertrophy in hypertensive type 2 diabetic patients. J Hypertens, 18(Suppl 2):s65.
27. Fogari R, Mugellini A, Zoppi A, et al. 2003. Differential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertension. Am J Hypertens, 16:596–9.
28. Grassi G, Seravalle G, Turri C, et al. 2003. Short-versus longterm effects of different dihydropyridines on sympathetic and baroreflex function in hypertension. Hypertension, 41:558–62.
29. Guarneri L, Angelico P, Ibba M, et al. 1996. Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine. Arzneimittelforschung, 46:15–24.
30. Guillen VFG, Abellan J, Llisterri JL, et al. 2003. Efficacy and safety of lercanidipine in combination with enalapril in HBP. Preliminary results of ZANYCONTROL study group. Am J Hypertens, 16:115A.
31. Hansson L, Hedner T, Lund-Johansen P, et al. 2000. Randomised trial of effects of calcium antagonists compared with diuretics and betablockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet, 356:359–65.
32. Hansson L, Lindholm LH, Ekbom T, et al. 1999. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet, 354:1751–6.
33. Herbette LG, Vecchiarelli M, Sartani A, et al. 1998. Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties. Blood Press Suppl, 2:10–7.
34. Hollenberg NK. 2002. Observations on the safety of lercanidipine: adverse event data from placebo-controlled trials. Am J Hypertens, 15: 58A–9.
35. Incandela L, Belcaro G, Cesarone MR, et al. 2001. Oxygenfree radical decrease in hypertensive patients treated with lercanidipine. Int Angiol, 20:136–40.
36. James IGV, Jones A, Davies P. 2002. A randomised, doubleblind, doubledummy comparison of the efficacy and tolerability of lercanidipine tablets and losartan tablets in patients with mild to moderate essential hypertension. J Hum Hypertens, 16:605– 10.
37. Kostis JB. 2003. Treatment of hypertension in older patients: an updated look at the role of calcium antagonists. Am J Geriatr Cardiol, 12: 319–27.
38. Leonetti G. 1999. The safety profile of antihypertensive drugs as the key factor for the achievement of blood pressure control: current experience with lercanidipine. High Blood Press, 8:92– 101.
39. Leonetti G, Magnani B, Pessina AC, et al. 2002. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens, 15:932–40.
40. Lund-Johansen P, Stranden E, Helberg S, et al. 2003. Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine. J Hypertens, 21:1003–10.
41. Luque M, Ruilope LM, Tamargo J, et al. 2004. Drug surveillance study in patients with mild to moderate hypertension treated with lercanidipine: the ZANYTEN study. Am J Hypertens, 20(Suppl 4):S163.
42. Macchiarulo C, Pieri R, Mitolo DC, et al. 2001. Antihypertensive effects of 6 calcium antagonists: evidence from Fourier analysis of 24-hour ambulatory blood pressure recordings. Curr Ther Res, 62:236–53.
43. Mallion JM, Allaert FA, Scart-Gres C, et al. 2004. Variations in the frequency of lower limb oedema in patients recieving lercanidipine in adjunction to their antihypertensive treatment. J Hypertens, 22(Suppl 2):S269.
44. Martell N, Lopez-Eady MD, Castro P, et al. 2004. Modifications of the pulse pressure in elderly hypertensives treated with lercanidipine. J Hypertens, 22(Suppl 2):S121.
45. Marx A, Lichtenthal A, Milbredt C, et al. 2004. Effect of anthypertensive therapy with a new third generation calcium antagonist lercanidipine on patients with concomitant diseases. J Hypertens, 22(Suppl 2):S236.
46. Messerli FH. 2002. Calcium antagonists in hypertension: from hemodynamics to outcomes. Am J Hypertens, 15:94S–7.
47. Millar-Craig M, Shaffu B, Greenough A, et al. 2003. Lercanidipine vs lacidipine in isolated systolic hypertension. J Hum Hypertens, 17: 799–806.
48. Morisco C, Trimarco B. 1997. Efficacy and tolerability of lercanidipine in comparison to and in combination with atenol in patients with mild to moderate hypertension in a double-bind controlled study. J Cardiovasc Pharmacol, 29:S26–30.
49. Motero J, Marques E, Eugenio JM, et al. 2002. Comparative study of the antihypertensive efficacy of lercanidipine in the treatment of mild to moderate high blood pressure in patients under and over 65 years old [abstract]. J Hypertens, 20(Suppl 4):S162.
50. Ninci MA, Magliocca R, Malliani A. 1997. Efficacy and tolerability of lercanidipine in elderly patients with mild to moderate hypertension in a placebo-controlled, double-blind study. J Cardiovasc Pharmacol, 29:S40–4.
51. Notarbartolo A, Rengo F, Scafidi V, et al. 1999. Long-term effects of lercanidipine on the lipoprotein and apolipopprotein prоfile of patients with mild-to-moderate essential hypertension. Curr Ther Res, 60: 228–36.
52. Omboni S, Zanchetti A; On behalf of the Multicenter Study Investigators. 1998. Antihypertensive efficacy of lercanidipine at 2.5, 5 and 10mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements. J Hypertens, 16:1831–8.
53. Pedrinelli R, Dell’Omo G, Nuti M, et al. 2003. Heterogeneous effect of calcium antagonists on leg oedema: a comparison of amlodipine versus lercanidipine in hypertensive patients. J Hypertens, 21:1969–73.
54. Policicchio D, Magliocca R, Malliani A. 1997. Efficacy and tolerability of lercanidipine in patients with mild to moderate essential hypertension: a comparative study with slow release nifedipine. J Cardiovasc Pharmacol, 29:S31–5.
55. Poncelet P, Ribstein J, Goullard L, et al. 2004. Efficacy and acceptability of lercanidipine are not age dependent in patients with essential hypertension: the AGATE study. Ann Cardiol Angeiol (Paris), 53: 123–30.
56. Rachmani R, Levi Z, Zadok BS, et al. 2002. Losartan and lercanidipine attenuate low-density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: a randomized, prospective crossover study. Clin Pharmacol Ther, 72:302–7.
57. Rengo F, Romis L. 1997. Activity of lercanidipine in doubleblind comparison with nitrendipine in combination treatment of patients with resistant essential hypertension. J Cardiovasc Pharmacol 29:S54–8.
58. Robles NR, Canelada JA, Iglesias M, et al. 2003. Evaluation of lercanidipine in the general practice setting. Ann Med Interna, 20: 282–6.
59. Robles NR, Pastor L, Manjon M, et al. 2004. Lercanidipine in diabetic patients with renal failure. Nefrologia, 24:338–43.
60. Robles NR, Ocon J, Gomez CF, et al. 2005. Lercanidipine in patients with chronic renal failure: The ZAFRA study. Ren Fail, 27:73–80.
61. Roma J, Sobrino J, Soler-Amigo J, et al. 2004. Treatment with lercanidipine during six months in hypertensive elderly patients (more than sixty years). J Hypertens, 20(Suppl 4):S391.
62. Romito R, Pansini MI, Perticone F, et al. 2003. Comparative effect of lercanidipine, felodipine, and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the Lercanidipine in Adults (LEAD) Study. J Clin Hypertens (Greenwich), 5:249–53.
63. Sabbatini M, Leonardi A, Testa R, et al. 2000a. Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension, 35:775–9.
64. Sabbatini M, Leonardi A, Testa R, et al. 2002. Effects of dihydropyridinetype Ca2+ antagonists on the renal arterial tree in spontaneously hypertensive rats. J Cardiovasc Pharmacol, 39:39–48.
65. Sabbatini M, Vitaioli L, Baldoni E, et al. 2000b. Nephroprotective effectoftreatmentwithcalciumchannelblockersinspontaneously hypertensive rats. J Pharmacol Exp Ther, 294:948–54.
66. Sangiorgi GB, Putignano E, Calcara L, et al. 1997. Efficacy and tolerability of lercanidipine vs captopril in patients with mild to moderate hypertension in a double controlled study. J Cardiovasc Pharmacol 29(Suppl 2):s36–9.
67. Sarafidis P, Lasaridis A, Hatzistavri L, et al. 2004. The effect of telmisartan and lercanidipine on blood pressure and insulin resistance in hypertensive patients. Rev Clin Pharmacol Pharmacokinet Int, 18: 60–6.
68. Schwinger RHG, Schmidt-Mertens A. 2002. The new lipophilic calcium channel blocker lercanidipine combines high antihypertensive efficacy with low side effects. Dtsch Med Wochenschr, 127(Suppl 1):s13.
69. Seravalle G, Stella ML, Foglia G, et al. 2002. Temporal profile of antihypertensive drug-induced regression of cardiac and vascular structural alterations in hypertension [abstract]. J Hypertens, 20:S190.
70. Sironi G, Montagna E, Greto L, et al. 1996a. Antihypertensive effects of lercanidipine in experimental hypertensive rats and dogs. Arzneimittelforschung, 46:145–52.
71. Sironi G, Montagna E, Greto L, et al. 1996b. Haemodynamic effects of lercanidipine in anaesthetized open-chest dogs. Arzneimittelforschung, 46:256–61.
72. Stergiou GS, Salgami EV. 2004. New European, American and International guidelines for hypertension management: agreement and disagreement. Expert Rev Cardiovasc Ther, 2:359–68.
73. Taddei S, Virdis A, Ghiadoni L, et al. 2003. Calcium antagonist treatment by lercanidipine prevents hyperpolarization in essential hypertension. Hypertension, 41:950–5.
74. Versari D, Virdis A, Ghiadoni L, et al. 2004. Lercanidipine restores nitric oxide availability in the forearm of essential hypertensive patients. Am J Hypertens, 15(Part 2):42A.
75. Viviani GL. 2002. Lercanidipine in type II diabetic patients with mild to moderate arterial hypertension. J Cardiovasc Pharmacol, 40:133–9.
76. Weir MR. 2003. Incidence of pedal edema formation with dihydropyridine calcium channel blockers: issues and practical significance. J Clin Hypertens (Greenwich), 5:330–5.
77. Wirtz S, Herzig S. 2004. Molecular mechanisms of vasoselectivity of the 1,4-dihydropyridine lercanidipine. Br J Pharmacol, 142:275–84.
78. [WHO] World Health Organization, International Society of Hypertension Writing Group. 2003. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens, 21:1983–92.
Рецензия
Для цитирования:
Борджи K. Лерканидипин при артериальной гипертензии. Кардиоваскулярная терапия и профилактика. 2009;8(7):121-129.
For citation:
Borghi C. Lercanidipine in arterial hypertension. Cardiovascular Therapy and Prevention. 2009;8(7):121-129. (In Russ.)
Просмотров:
1417
Послать статью по эл. почте 
